6-(4-(1,1-Dimethylethyl)phenoxy)-3-pyridinamine
Adenoid Cystic Carcinoma
Explore 11 assets in Adenoid Cystic Carcinoma →Floatz Rating
D26/100
Confidence
Indicative
Sponsor
Cellestia Biotech AG
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
11Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03422679CT.gov Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adenoid Cystic Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 6-(4-(1,1-Dimethylethyl)phenoxy)-3-pyridinamine (this asset) | Cellestia Biotech AG | P1/2 | D · 26 |
| Cetuximab | Fox Chase Cancer Center | P1/2 | B |
| Irinotecan | National Cancer Institute (NCI) | P1/2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | CCC |
| Vipivotide Tetraxetan | Maria Sklodowska-Curie National Research Institute of Oncology | P2 | CCC |
| Everolimus | Emory University | P1 | CCC |
| Pembrolizumab | Seagen, a wholly owned subsidiary of Pfizer | P1/2 | CCC |
| Recombinant Interleukin-12 | National Cancer Institute (NCI) | P1 | CC |
+20 more in the Adenoid Cystic Carcinoma cohort
Other indications for 6-(4-(1,1-Dimethylethyl)phenoxy)-3-pyridinamine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P2 | D · 30 |
| Leukemia | — | P2 | D · 29 |
| Acute Lymphoblastic Leukemia | — | P2 | D · 29 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 6-(4-(1,1-Dimethylethyl)phenoxy)-3-pyridinamine in Adenoid Cystic Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/6-4-11-dimethylethylphenoxy-3-pyridinamine-adenoid-cystic-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →